Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Agreement expands Mycovia’s commercialization that is global for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States

Mycovia will continue to quickly develop VT-1161 as a prospective first FDA-approved remedy for recurrent vulvovaginal candidiasis

DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into an exclusive permit and development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, an dental product that is antifungal, happens to be in period 3 medical trials for the remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million ladies worldwide every year.

“We are excited to partner with Gedeon Richter, an organization with strong market leadership in women’s health, to build up and commercialize VT-1161, our possible first treatment that is FDA-approved RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. دنباله این نوشته …